

## Menarini Group benefit from increased oversight, compliance and efficiency in literature screening for pharmacovigilance using Drug Safety Triager™

Many pharmaceutical companies face a growing challenge to review the scientific literature for Individual Case Safety Reports (ICSRs) and other safety relevant information. This is a consequence of the rising volume of literature that needs to be assessed.

For example, every day around 6,000 peer-reviewed articles are published in

roughly 10,000 journals; in 2020 the volume of literature available for review grew by 10%. In addition, even with precision search only approximately 5% of literature search results contain a valid ICSR. There is also pressure to demonstrate meeting KPIs and to be inspection ready, as well as the desire to cut costs while maintaining full compliance.

peer-reviewed articles are published in roughly 10,000 journals.



Drug Safety Triager really helps us to have a complete and automatic overview on the oversight of the process. Thanks to DST Menarini has put in place a faster and safer Literature Screening process with a high quality standard. Every minute saved is a minute gained!

Our customer (Menarini Group) had a need to change the technology they were using for literature screening.

In addition, they were looking to introduce improvements in their process. Specifically, Menarini needed to improve oversight of the process. They wanted to be able to monitor the performance of both their internal screeners as well as their external partners. Menarini Group are now using Drug Safety Triager to review the literature published about their products. The literature is retrieved by alerts set up on the Dialog® platform.

Dialog alert results are then output into our Drug Safety Triager where they are manually reviewed for ICSR and other safety relevant information. By using Drug Safety Triager they were able to see Dashboards configured to show metrics such as how many

references are awaiting review for each stage of the literature screening workflow. Clicking on any of the numbers generates a report with full details and a detailed view of each literature reference screened or awaiting screening. Other dashboard cards provide progress to completion work status and various useful operational stats at glance. A comprehensive ad-hoc report can be used in analysis and overall oversight of the workflow.

Another requirement was to be able to record every action in the literature screening process from receipt and logging of Day Zero to submission for case processing, medical writing for aggregate reporting and to signal evaluation.

The Drug Safety Triager offers an exportable, searchable audit trail which gives Menarini Group additional oversight and, together with the administration audit report, instant inspection readiness and a reduction in risk of errors or missed or inconsistent process.

Duplicate references can add to the cost and time taken to review caused by the volume of literature available for screening. The Drug Safety Triager reduces duplicate references by tagging multiple relevant drugs to each reference, as well as offering manual deduplication where users can manually make an additional judgment on duplicates.

Menarini Group have reported increased efficiency due to fewer duplicate references and improved oversight of both internal screeners and of their outsource partners.

Clarivate is delighted to support Menarini Group with Drug Safety Triager.

## **About Clarivate**

Clarivate is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

To find out more about our end-to-end pharmacovigilance literature monitoring solution and for a demo of our Dialog and Drug Safety Triager platforms, get in touch with us:

dialog.support@clarivate.com

- +1 800 334 2564 (North America)
- +44 800 029 3289 (Rest of World)

To learn more about how we can support your medical literature screening activity, visit our website: <a href="mailto:clarivate.com/pv">clarivate.com/pv</a>

Contact our experts today:

- +1 215 386 0100 (U.S.)
- +44 (0) 20 7433 4000 (Europe)

clarivate.com

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.